NEOVASCULOSTOP – An early-stage research project with the approach to elicit a paradigm shift in how we design future drug delivery strategies to the retina. The novel strategy of drug targeting will not only enrich the modified molecules in retinal tissue but will also reduce the therapeutic oral dose compared to existing anti-angiogenic therapy thereby increasing the safety of the treatment.
Innovation radar (https://innovation-radar.ec.europa.eu) has recognised the NeoVasculoStop project funded by the European Commission under Horizon Europe as highlighted excellent innovation. In this analysis Innovation Radar also identified the following project partner(s) in the project as a ‘Key Innovator’ in the development of this innovation:
VICHEM CHEMIE KUTATÓ KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG